<p>Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis</p>

Abstract

BackgroundThe aim of the study was to compare drug survival rate of subcutaneous tumor necrosis factor alpha inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients in Hungary.MethodsThis was a retrospective analysis using data collected from 5,647 patients over a period of 10 years who were treated with any of the following drugs: adalimumab (ADA), etanercept, certolizumab pegol (CZP), and golimumab (GLM). National Health Insurance Fund’s hospital, drug reimbursement, and special reimbursement registry data have been used in this study. Drug survival rate was calculated according to Kaplan–Meier survival analysis. Propensity score matching was used to reduce the potential bias caused by the inhomogeneity resulting from demographic characteristics, patient pathways, or drug administration protocols. Both raw and propensity matched data were subject of pairwise comparison between the four subcutaneous therapies.ResultsThe overall rate of persistence for the 4 biological therapies was between 53% and 61% after 1 year and between 14% and 19% after 4 years (follow-up time). Pairwise comparisons between therapies showed significant differences with GLM-treated patients showing longer median survival times than patients on other therapies. After propensity matching, these differences remained statistically significant between GLM and ADA or CZP over 4 years.ConclusionHungarian show longer persistence to GLM compared to ADA and CZP.

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

“…Due to its long-term duration, BioTRAC offered a unique opportunity to evaluate the real-world effectiveness and safety of three anti-TNF agents in a community Canadian setting, while assessing regional variations due to differences in patient profiles, practice patterns and local reimbursement policies impacting access to care over 16 years. Although there has been extensive real-world evidence generated on the early anti-TNF agents such as IFX or etanercept, very little efficacy data has been published with other anti-TNF agents such as GLM, and most of those only presented persistence data [15,[29][30][31]. One exception, however, is the GO NICE prospective non-interventional trial in Germany for inflammatory arthritis patients treated with GLM [15,32].…”

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Canadian Prospective Observational Registry

“…Due to its long-term duration, BioTRAC offered a unique opportunity to evaluate the real-world effectiveness and safety of three anti-TNF agents in a community Canadian setting, while assessing regional variations due to differences in patient profiles, practice patterns and local reimbursement policies impacting access to care over 16 years. Although there has been extensive real-world evidence generated on the early anti-TNF agents such as IFX or etanercept, very little efficacy data has been published with other anti-TNF agents such as GLM, and most of those only presented persistence data (15,(29)(30)(31). One exception, however, is the GO NICE prospective non-interventional trial in Germany for inflammatory arthritis patients treated with GLM (15,32).…”

¿Qué dice la literatura de la persistencia de los fármacos que utilizamos por ley Ricarte Soto en Artritis Reumatoide?

“…En cuanto a certolizumab, un análisis retrospectivo de una cohorte brasileña de 66.787 pacientes entre el año 2006 al 2014, concluyó que certolizumab e infliximab presentaron las tasas de persistencia más bajas en comparación a otros biológicos, siendo de 42,83% para certolizumab 32 . Otro análisis de una base de datos de 5.647 pacientes húngaros entre el año 2010-2016, mostró una persistencia de 53% para certolizumab a los 12 meses 33 .…”